News

The preferred vendor agreement will streamline the Intertek purchasing process for PerkinElmer products worldwide and is expected to be valued at several million dollars. “As an organization focused

As part of the agreement, the two companies will jointly market their services to biomedical companies, insurers and government agencies worldwide. World Health Information Science Consultants (WHISCON) will

This is a single pivotal study designed to support applications to market ASA404 for lung cancer patients who have received one previous round of treatment. A separate, ongoing

This approval enables the company to market its line of bioresorbable implants for bone and/or soft tissue repair in the EU. Orthomimetics’s family of products was developed during

In all available and eligible patients assessed at 12 months post-treatment, more than seven times as many positive responses to treatment were documented in patients who received the

Under this partnership, BioLeap and Jubilant will integrate BioLeap’s computational fragment based drug design platform with Jubilant’s expertise in chemistry, biology and crystallography to offer a highly competitive

Regulatory approvals have also been obtained and dosing will begin shortly in two additional trials: a randomized Phase II study to evaluate NKTR-102 versus irinotecan in second-line colorectal

The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer, said Abbott. The new assay uses

The milestone payment of E2.5 million was triggered by enrolling the seventh patient in the multinational Fentanyl Taifun Phase III program in late December 2008. Enrollment is ongoing